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ABSTRACT 
Background: Active surveillance (AS) for prostate cancer (PCa) includes follow-up with serial 
prostate biopsies. The optimal biopsy frequency during follow-up has not been determined. The 
goal of this investigation was to use longitudinal AS biopsy data to assess if the frequency of 
biopsy could be reduced without substantially prolonging the time to detection of Gleason ≥7 
disease. 
Methods: Using data from 1375 men with low-risk PCa enrolled in AS at Johns Hopkins, we 
developed a hidden Markov model (HMM) to estimate the probability of under sampling at 
diagnosis, the annual probability of grade progression, and the 10-year cumulative probability of 
reclassification or progression to Gleason ≥7. We simulated 1024 potential AS biopsy strategies 
for the 10 years following diagnosis. For each of these strategies the model predicted the mean 
delay in detection of Gleason ≥7 disease. 
Results: The model estimated 10-year cumulative probability of reclassification from Gleason 6 
to Gleason ≥7 was 46.0%. The probability of under sampling at diagnosis was 9.8% and the 
annual progression probability for men with Gleason 6 was 4.0%. Based on these estimates, 
simulation of an annual biopsy strategy estimated the mean time to detection of Gleason ≥7 
disease to be 14.1 months; however, several strategies eliminated biopsies with only small (<12 
months) delays in detecting grade progression. 
Conclusions: While annual biopsy for low-risk men on AS is associated with the shortest time to 
detection of Gleason ≥7 disease, several alternative strategies may allow for less frequent biopsy 
without sizable delays in detecting grade progression. 
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INTRODUCTION 
Although prostate cancers often demonstrate indolent clinical behavior (1), many men with low-
risk tumors still receive surgery or radiation therapy, both of which are associated with 
potentially serious complications including incontinence, impotence, and other side effects (2). 
These complications are particularly distressing given that evidence shows that these men may 
not survive longer with surgery or radiation than they do with expectant management 
approaches. Active Surveillance (AS) is a form of expectant management that involves 
monitoring patients by conducting regular clinical exams, biomarker tests, radiologic imaging, 
and biopsies. Due to concerns that many men who are diagnosed with prostate cancer are 
overtreated, AS has been promoted as a way for low-risk men to delay and possibly avoid 
surgery or radiation treatment. However, many approaches to implementing AS have been 
recommended and the best approach is unclear (3).  
Due to a lack of evidence in support of a single optimal AS strategy, it is left to individual 
urologists and patients to decide how frequently to conduct follow-up biopsies. No previous 
study has made a link between different AS follow-up strategies and the delay in the detection of 
progression to high-grade cancer. Risk of progression is one of the most important considerations 
when weighing long-term risk for patients on AS. The ideal strategy to minimize risk of delaying 
the detection of high-grade cancer progression is to biopsy patients frequently (e.g. annually as 
suggested by Tosoian et al. (4)). However, this risk competes with the harms of frequent biopsies 
resulting in pain and anxiety for patients, and the potential for complications, such as infection. 
Severe infection rates for biopsy are approximately 1-2% (5); however, recent studies suggest 
that infection rates for patients undergoing AS increases as a function of the number of biopsies 
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they have received (6). Studies have observed discontinuation of AS by patients without signs of 
progression (7) and some have suggested that reducing surveillance biopsies may encourage 
compliance with AS (8). 
In this context and using data from a large longitudinal AS cohort, we set out to determine if the 
number of biopsies received over 10 years of AS could be reduced from an annual biopsy 
schedule without substantially increasing the time to detecting grade progression in cases where 
it occurred. In order to do this, we used longitudinal data from the Johns Hopkins AS study to 
conduct a hidden Markov model analysis to estimate initial biopsy sampling error, biopsy 
accuracy, and the rate of progression from low to intermediate or high-grade prostate cancer over 
time. We further conducted model validation and sensitivity analysis. Finally, we used the model 
to evaluate all possible follow-up surveillance strategies as well as previously proposed strategies 
for AS found in the literature on the basis of mean delay time to detect grade progression and the 
planned number of biopsies over the first 10 years following initiation of AS. 
METHODS 
Data  
The Johns Hopkins AS study data included men enrolled in AS from 1992 to 2015. The study 
enrolled men with “favorable risk” prostate cancer: clinical stage ≤T1c, PSA density ≤0.15, 
Gleason score ≤6, total positive cores ≤2, and single core positivity ≤50\%. Due to patient 
preference, older men with low-risk disease (i.e., clinical stage ≤T2a, PSA <10 ng/mL, and 
Gleason score ≤6) were also enrolled in the study. The cohort was predominantly comprised of 
men with low volume Gleason score 6 prostate cancer (< 3 cores and <50% core involvement). 
The data collected included PSA, age, and annual biopsy results (e.g., Gleason score, number of 
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positive cores, maximum percentage core involvement). The Johns Hopkins protocol includes 
semiannual PSA and digital rectal examination and annual prostate biopsy. If a patient’s biopsy 
results no longer meet the inclusion criteria, they are recommended for curative treatment. The 
dataset used was anonymized with respect to patient identifiers and approval of the University of 
Michigan IRB was obtained prior to initiation of the study.  
Hidden Markov Model for Prostate Cancer Grade Progression 
The specific type of model we employ is a hidden Markov model (HMM) in which patient’s 
progress through health states as defined by their prognostic grade groups based on Gleason 
score, the most important clinical factor for assessing risk of prostate cancer mortality. The term 
hidden refers to the fact that the exact health state of the patient is unknown, in the absence of 
prostatectomy. The probability of progression to a higher prognostic grade group is determined 
by transition probabilities. We use the term “progression” to refer collectively to reclassification 
based on under sampling of existing higher grade lesions, true evolution of Gleason pattern 3 
into pattern 4, or the occurrence of a “de novo” higher grade cancer. We based the model on one-
year time periods between state transitions to be consistent with the highest proposed frequency 
of biopsies and because that was the planned frequency of biopsies in the Johns Hopkins study.  
We used the Baum-Welch algorithm to compute maximum likelihood estimates for the HMM 
parameters (9). The Baum-Welch algorithm is a special case of the general expectation-
maximization (EM) algorithm (10), an iterative algorithm that combines forward and backward 
passes on a longitudinal observation sequence to find the choice of transition probabilities, 
observation probabilities, and initial distribution of patients that maximizes the likelihood of 
observing the collection of observed sequences. To initiate the Baum-Welch algorithm, we 
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needed initial estimates of the model parameters: annual progression rate from Gleason score ≤ 6 
to Gleason score ≥ 7, the sensitivity and specificity of biopsy to Gleason score ≥ 7 disease, and 
the initial proportion of patients undergoing AS with Gleason score ≤ 6 disease. These estimates 
are not directly observable in the dataset, because biopsies are imperfect; thus, we used estimates 
from the literature to initialize the algorithm. Alam 2015 (11) studied reclassification rates for 
men in the Johns Hopkins AS study, and found that the majority of men are reclassified within 
the first two years, most likely due to initial biopsy misclassification. We estimated annual rate 
of evolution from Gleason score ≤ 6 to Gleason score ≥ 7 or for development of a de novo 
Gleason score ≥ 7 cancer to be 5% by calculating the rate of progression at patient’s third 
through thirteenth biopsies. Estimates for the sensitivity and specificity of biopsy to Gleason 
score ≥ 7 disease were calculated to be 62.5% and 89.4%, respectively, based on data reported in 
Epstein et al. (12), which compared biopsy results to Gleason score at radical prostatectomy. 
Finally, using data reported in Epstein et al. (2012), we estimated that 74.9% of patients 
diagnosed with Gleason score ≤ 6 disease on biopsy have Gleason score ≤ 6 disease at radical 
prostatectomy, while 25.1% have Gleason score ≥ 7 disease at radical prostatectomy. We used 
these estimates as the starting points for the Baum-Welch algorithm, and we ran the algorithm 
using a stopping criteria defined by a tolerance of 10
-6
 on the difference between the log 
likelihoods for consecutive iterations.  
We used the resulting model to evaluate a large number of AS biopsy schedules, including 
schedules proposed in the literature. University of California, San Francisco (UCSF) 
recommends a biopsy 1 year after diagnosis, then every 1 to 2 years. We modeled two versions 
of this policy: UCSF1 performs a biopsy after 1 year, then every 1.5 years and UCSF2 performs 
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a biopsy after 1 year, then every 2 years (13). PRIAS/University of Toronto (UT) performs a 
biopsy after 1, 4, 7, and 10 years (14).  
Simulation Model 
We used the HMM parameter estimates to simulate mean delay time in detecting progression 
among patients who progress to high-grade cancer over the 10-year period following diagnosis 
of prostate cancer for all 2
10
 possible AS biopsy strategies. The delay time depends on the HMM 
parameter estimates, which include the initial probability a patient has Gleason score ≤ 6 or 
Gleason score ≥ 7 at the time of diagnosis, the annual transition probability from Gleason score ≤ 
6 to Gleason score ≥ 7, and the sensitivity and specificity of biopsy to Gleason score ≥ 7 disease. 
Together with the AS biopsy schedule these parameters collectively govern the time to reach the 
high-grade cancer state and subsequent detection of grade progression. We defined the biopsy 
schedule as a vector of binary decision variables that indicated whether a biopsy is planned at a 
particular time period or not. We then simulated all 2
10
 possible AS strategies and evaluated 
mean time to detect Gleason score ≥7 cancer. Finally, we identified those strategies that were 
non-dominated, i.e., those strategies for which no other strategy simultaneously recommended 
fewer biopsies and had lower mean time to detect high-grade cancer.  
Model Validation and Sensitivity Analysis 
To validate the results obtained, we used the base case estimates of our model to simulate the 
detection rate based on 10,000 samples assuming annual biopsy as planned in the Johns Hopkins 
AS study protocol, and compared the results to the observed detection rates in the Johns Hopkins 
data.  
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Next, we conducted experiments based on a hypothetical HMM for which we knew the true 
values for model parameters, and we tested our implementation of the Baum-Welch algorithm on 
sampled results for 1375 simulated patient observation sequences, which is the number of 
patients in the study who received their first surveillance biopsy. Since there were missing data 
in the Johns Hopkins study resulting from patients who discontinued AS in the absence of grade 
progression, we sought to test the assumption that the missing data were not informative. 
Therefore, we censored the data for simulated observation sequences according to the observed 
mean rate of patients discontinuing AS without grade progression. We then ran the Baum-Welch 
algorithm on the simulated data and compared the parameter estimates to the true parameters 
used to generate the simulated data.  
To validate that the resulting parameter estimates were not sensitive to the initial parameter 
estimates, we varied our initial estimate for each parameter using a range of ±0.1 with an upper 
limit of 0.99. We then ran the Baum-Welch algorithm on each new set of initial estimates, and 
compared the resulting parameter estimates. We further performed bootstrapping analysis for 
which we randomly sampled 1375 patients with replacement from the Johns Hopkins dataset. 
We generated 30 different bootstrap samples and ran the Baum-Welch algorithm on each sample, 
and compared the resulting parameter estimates. 
Finally, we performed analysis to assess the potential error in HMM parameter estimates due to 
missing data for patients who left the study for reasons other than grade progression. We 
generated 100 different simulated datasets using a hypothetical model based on parameters from 
our base case analysis. For each dataset, we sample 1375 patients with patient dropout based on 
point estimates of the dropout rate in the cohort. We then ran the Baum-Welch algorithm for 
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each of the 100 simulated datasets and compared the resulting parameter estimates to the base 
case results.  
RESULTS 
 
Data 
There were 1521 patients in the dataset and we removed 22 patients from the dataset due to 
missing diagnostic biopsy information. Table 1 describes the patient characteristics at diagnosis 
of the remaining 1499 patients. Among men who discontinued AS and received treatment, 50.9% 
received surgery and 46.2% received radiation therapy. The mean and variance of the time 
between biopsies was 14.2 and 60.1 months, respectively. The median number of biopsies per 
patient, including diagnosis biopsy, was 3 and ranged from 1 to 14. Table 2 shows the biopsy 
characteristics, where we have defined progression to be transition from a Gleason score ≤ 6 to 
Gleason score ≥ 7 on biopsy. Due to this definition, we excluded  six additional patients initially 
diagnosed with Gleason 7 disease from the analysis in Table 2. Among the remaining patients 
there were 1375 patients who had at least one surveillance biopsy following the diagnosis 
biopsy. The median time between biopsies was one year and the biopsy compliance for the first 
two years is 90%. The 6-year compliance rate for men < 75 years is 80% and 50% in men > 75 
years. 
Hidden Markov Model Analysis 
Using the Baum-Welch algorithm, we estimated the annual progression rate from Gleason score 
≤ 6 to Gleason score ≥ 7 to be 4.0%; the sensitivity and specificity of biopsy to Gleason score ≥ 7 
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disease to be 61.0% and 98.6%, respectively; and the initial proportion of patients under sampled 
at the time of diagnosis, with Gleason score ≥ 7 disease, to be 9.8%. 
Simulation Model of AS Strategies 
Our simulation model found that 40% of patients progress to higher-grade cancer in 10 years, 
and that a strategy that performs annual biopsies (the Johns Hopkins strategy) takes a mean of 
14.1 months to detect progression. The strategy that minimized the mean delay time for each 
choice of planned number of biopsies over 10 years are plotted in Figure 1, which shows the 
incremental time to detection and the reduction in biopsies relative to a strategy that performs 
annual biopsies. Figure 1 shows that UCSF performs well compared to the optimal policy, while 
the PRIAS/UT increases mean time to detection by 5.2 months compared to an optimal policy 
that performs the same number of biopsies, at years 1, 3, 5, and 8. The optimal policy performs 
biopsies earlier than the PRIAS/UT policy.  
The simulation model found that 13.5%, 4.9%, and 1.8% of patients would be detected more 
than 12 months, 24 months, and 36 months after grade progression, respectively. Table 3 
presents the increased risk of varying biopsy schedules relative to the annual schedule. For 
example, policy F eliminates six biopsies in the first 10 years of active surveillance, while only 
increasing a patient’s risk of being detection with grade progression after more than 24 months 
by 9.8% relative to an annual biopsy strategy. Table 3 also shows that our optimal policies 
perform better than the published policies using the same number of biopsies. For example, 
policies F and the PRIAS policy both perform four biopsies in the first 10 years of active 
surveillance; however, policy F decreases a patient’s risk of >24 months to detect grade 
progression by 3.6 percentage points compared to the PRIAS policy. 
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HMM Validation and Sensitivity Analysis 
To validate the results obtained, we used the base case estimates of our model to simulate the 
detection rate assuming annual biopsy as planned in the Johns Hopkins AS study protocol. 
Figure 2 shows the difference in model-based results and the observed results were small. Model 
predicted results were based on 10,000 samples.  
Modifications to the definition of Gleason 6 versus 7 by the International Society of Urological 
Pathology in 2005 may have caused changes to the rate of grade reclassification. For this reason, 
we also performed a second analysis on only those patients diagnosed during or after 2005 
(n=995). Results for annual progression were slightly higher (4.6% versus 4%) and the 
misclassification rate was slightly lower (8.7% versus 9.8%), as would be expected from more 
stringent criteria. 
Results for the hypothetical HMM for which the true values for model parameters are known are 
presented in Table 4, which shows the true model parameters from the hypothetical model and 
the 95% confidence interval for our model parameter estimates based on the Baum-Welch 
algorithm applied to 1000 sets of simulated biopsy data with 1375 sequences (i.e., the number of 
patients who received surveillance biopsies in the Johns Hopkins cohort) per set.  
After varying starting points of model parameters, we found the resulting parameter estimates 
varied by less than 0.5% from the values calculated using our original starting points, suggesting 
that starting points did not significantly impact our parameter estimates. The 95% confidence 
intervals based on bootstrapping are presented in Table 5, with sensitivity of biopsy to Gleason 
score ≥ 7 prostate cancer having the most variation. 
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In the final sensitivity analysis, we fit HMMs to 100 simulated datasets that emulated the 
characteristics of missing data in the cohort as described in the Methods section. We used the 
results of the base case analysis to define the true model parameters and simulated observations 
in the context of missing data due to patient dropout. The mean and 95% confidence intervals for 
progression, biopsy sensitivity and specificity, and misclassification due to under sampling were 
4.00% [3.98%, 4.02%], 62.5% [59.8%, 64.77], 98.76 [98.48, 99.04], and 8.96 [8.16, 9.76]. These 
simulated results compare very favorably with the base case results suggesting it is reasonable to 
assume that missing data due to patient drop out is not informative.  
DISCUSSION 
AS for prostate cancer includes follow-up with serial prostate biopsies; however, the optimal 
biopsy frequency during follow-up has not been determined. The goal of this investigation was 
to use longitudinal AS biopsy data to assess if the frequency of biopsy could be reduced without 
substantially prolonging the time to detection of Gleason ≥7 disease. Using longitudinal data 
from 1375 men with “favorable-risk” PCa enrolled in AS at Johns Hopkins who received at least 
one surveillance biopsy, we developed a HMM to estimate the probability of under sampling at 
diagnosis, the annual probability of grade progression, and the 10-year cumulative probability of 
reclassification or progression to Gleason ≥7. We simulated 1024 potential AS biopsy strategies 
for the 10 years following diagnosis and predicted the mean delay in detection of Gleason ≥7 
disease. While annual biopsy for low-risk men on AS is associated with the shortest time to 
detection of Gleason ≥7 disease, several alternative strategies may allow for less frequent biopsy 
without sizable delays in detecting grade progression. 
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Many experts have called for the use of AS to address overtreatment concerns for men with low-
risk prostate cancer. AS delays and possibly avoids immediate treatment via surgery or radiation 
therapy until and unless there is evidence that the disease has progressed; however, it comes with 
a burden to patients due to the need to conduct follow-up clinical exams, tests, and surveillance 
biopsies. The intensiveness of follow-up determines the frequency of clinical exams, tests, and 
biopsies. In the absence of randomized trials comparing AS pathways there is no consensus 
among urologists about the best way to tradeoff the burden of surveillance with the benefits of 
avoiding cancer progression (15). We provide a new model for AS that  quantifies the tradeoff 
between benefits and harms of various AS strategies. These decisions must tradeoff between the 
potential long-term benefits of detecting disease progression with the burden of surveillance, 
including the potential harms and side effects of biopsies (e.g. pain, anxiety, and hospitalization 
for infection in 2–3% of cases).  
There are multiple definitions of progression for prostate cancer, including definitions based on 
increase in PSA, PSA velocity and density, and tumor volume. Grade progression, which refers 
to a change in Gleason score, is a definitive form of progression recognized by all published AS 
guidelines. However, currently there is debate about whether grade progression is possible, or if 
the occurrence of higher grade cancer on biopsy occurs due to biopsy sampling error. Some 
studies suggest that a combination of sampling error, true progression, and development of a de 
novo cancer are responsible for increased grade detection over time (14,16). Our findings lend 
additional evidence to these studies, suggesting a combination of mechanisms are responsible for 
detection of higher grade cancers in the future.  This suggests there may be benefits to more 
frequent biopsies following diagnosis and less frequent biopsies in later years. This is supported 
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by our simulation results. If grade progression does not occur, as some believe, then the 
incremental time to detection reported in Figure 2 would be even lower.  
A chief concern about AS is the possibility that prostate cancer progresses in the interval of time 
between biopsies or that progression is missed due to imperfect sensitivity of biopsies. The 
potential for undetected progression raises questions about health outcomes for patients on AS 
who progress and receive treatment. Studies comparing radical prostatectomy outcomes for 
patients initially on AS to patients receiving radical prostatectomy immediately following 
diagnosis have shown that low-risk men who receive annual biopsy on AS do not have worse 
surgery outcomes (4). Additionally, Klotz et al. reported that patients undergoing AS with 
biopsies every 3 to 4 years had mortality rates consistent with patients who received initial 
definitive treatment (17). Assuming a uniform distribution of progression times during the 3 to 4 
years intervals would suggest delays of approximately 18 to 24 months in detecting grade 
progression may not have a clinically significant impact. Our results suggest that reducing the 
number of biopsies by half (compared to an annual biopsy strategy) would result in an 
incremental increase in time to detection of grade progression that is well below these estimates. 
Our results pertain to patients with Gleason 6 disease and they are not informative for patients 
with Gleason 7 disease, particularly 3+4, some of whom may be good candidates for active 
surveillance. However, there is no clear consensus on acceptable safe cancer volume limit for 
patients with Gleason 3+4. Therefore, this remains an important question for future study (18). 
Our findings are not applicable to patients enrolling into AS with Gleason  7 disease. 
Nevertheless, Liu et al. reported that 80% of patients enrolling in active surveillance are 
diagnosed with Gleason 6 disease, so our results would be applicable to the majority of patients 
enrolling in active surveillance (19). 
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Our study has some notable limitations. First, our results apply to patients with “favorable risk” 
prostate cancer (i.e., clinical stage ≤T1c, PSA density ≤0.15, Gleason score ≤6, total positive 
cores ≤2, and single core positivity ≤50%) and older men with low-risk disease (i.e., clinical 
stage ≤T2a, PSA <10, and Gleason score ≤6), since these are the patients that were enrolled in 
the Johns Hopkins AS study and thus there is a need to validate our findings on other active 
surveillance studies; however, this initial study lays the groundwork for such future validation 
work. Our results provide the trade-off between number of biopsies and mean delay time to 
detection of progression; however, the amount of time that is considered safe to delay detection 
is not known. Nevertheless, data from the literature provide evidence that short delay times do 
not have significant clinical impact. Metastasis is a better endpoint, but the data needed to fit a 
hidden Markov model with this endpoint do not yet exist.  
Although compliance to annual biopsies in this cohort was high, making it an ideal source for the 
hidden Markov model analysis we presented, it was not perfect. Moreover, there was patient 
dropout for reasons other than biopsy confirmed progression. Thus, there is the potential for 
selection bias to influence the results. While this cannot be eliminated, we mitigated this risk in 
part by conducting simulation analyses that showed the hidden Markov model analysis was not 
sensitive to missing data. Finally, our model assumes that progression rates do not vary over time 
and that PSA is not used to initiate treatment. We do not believe this is a strong assumption, 
because PSA kinetics are not used to trigger intervention in the Johns Hopkins study. These 
limitations notwithstanding, we believe this study provides important evidence about the trade-
off between varying active surveillance strategies and the optimal timing of biopsies during 
active surveillance.  
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While annual biopsy for low-risk men on AS is associated with the shortest time to detection of 
Gleason ≥ 7 disease, several alternative strategies may allow for less frequent biopsy without 
clinically significant increases in time to detecting grade progression. For instance, based on 
model results, performing biopsies in years 1, 3, 5, and 8 would increase the time to detection by 
less than a year compared to an annual biopsy schedule that over a 10 year period. Additionally, 
the optimal model-based biopsy schedules tend to perform more biopsies in the beginning due to 
the risk of under sampling. External validation of the results using other AS studies is warranted 
to assess the degree to which surveillance biopsies can be safely attenuated.  
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Figure Legends 
Figure 1: Simulation results for non-dominated AS strategies from 2
10
 simulated strategies and 
published strategies based on the estimated HMM parameters. Incremental time to detection and 
the reduction in biopsies are relative to an annual biopsy strategy. (Note: mean time to detection 
of grade progression for annual biopsy plan = 14.1 months) 
Figure 2: Difference between the biopsy detection rate predicted by the simulation model and 
the observed rate in the Johns Hopkins study. Model predicted results were based on 10,000 
samples. The confidence intervals for the observed results are shown, and the confidence 
intervals for the model predicted results are too small to see on the figure. 
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Table 1: Patient characteristics at time of diagnosis. 
Characteristic  AS cohort (N = 1499) 
Age at diagnosis, yr (%)  
 ≤ 49 18 (1.2) 
 50–59 208 (13.9) 
 60–69 911 (60.8) 
 70–79  352 (23.5) 
 ≥ 80 10 (0.7) 
Race, no. (%)  
 White 1314 (87.7) 
 Black 115 (7.7) 
 Other 60 (4.0) 
 NA 10 (0.7) 
PSA at diagnosis, ng/mL  
 0–2.5 162 (10.8) 
 2.5–4 249 (16.6) 
 4–6 558 (37.2) 
 6–10 322 (21.5) 
 > 10 85 (5.7) 
 NA 123(8.2) 
PSA density at diagnosis  
 0–0.05 166 (11.1) 
 0.05–0.10 538 (35.9) 
 0.10–0.15 428 (28.6) 
 0.15–0.20 134 (8.9) 
 > 0.20 114 (7.6) 
 NA 119 (7.9) 
Gleason score at diagnosis, no. (%)  
 ≤ 6 1488 (99.3) 
 3+4 5 (0.3) 
 4+3 1 (0.1) 
 NA 5 (0.3) 
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Table 2: Biopsy characteristics at diagnosis and surveillance biopsies. 
Characteristics Biopsy 
Diagnosis First Second Third Fourth Fifth Sixth Seventh 
Patients, n 1493 1370 922 644 447 298 187 122 
Age at biopsy, yr, mean (SD) 66 (6.0) 67 (6.1) 67 (6.0) 68 (5.5) 68 (5.3) 69 (5.1) 70 (5.1) 71 (4.3) 
Months since last biopsy, no, mean (SD) 0 (0.0) 13 (8.2) 15 (7.5) 15 (7.1) 16 (8.6) 15 (6.9) 16 (7.6) 14 (3.9) 
Most recent PSA, ng/mL, mean (SD) 5.3 (2.9) 5.4 (3.4) 5.5 (4.1) 5.5 (4.0) 5.9 (4.9) 5.9 (4.2) 6.4 (5.1) 6.0 (4.7) 
Most recent PSA density, mean (SD) 0.12 (0.07) 0.11 (0.07) 0.11 (0.08) 0.10 (0.07) 0.10 (0.09) 0.10 (0.07) 0.10 (0.08) 0.09 (0.07) 
No. of biopsy cores, median (range) 12 (6–58) 12 (4–31) 12 (6–60) 12 (6–28) 12 (8–18) 12 (6–16) 14 (6–24) 14 (6–15) 
Percentage of cores positive for cancer, n (%)         
0 0 (0.0) 568 (41.5) 435 (47.2) 336 (52.2) 237 (53.0) 154 (51.7) 97 (51.9) 57 (46.7) 
>0 and <34% 808 (54.1) 624 (45.5) 415 (45.0) 271 (42.1) 188 (42.1) 129 (43.3) 79 (42.2) 58 (47.5) 
≥34% 10 (0.7) 58 (4.2) 20 (2.2) 7 (1.1) 9 (2.0) 5 (1.7) 5 (2.7) 2 (1.6) 
NA 675 (45.2) 120 (8.8) 52 (5.6) 30 (4.7) 13 (2.9) 10 (3.4) 6 (3.2) 5 (4.1) 
Gleason score, n (%)         
No cancer 0 (0.0) 568 (41.5) 435 (47.2) 336 (52.2) 237 (53.0) 154 (51.7) 97 (51.9) 57 (46.7) 
≤ 6 1488 (99.7) 670 (48.9) 413 (44.8) 275 (42.7) 181 (40.5) 130 (43.6) 78 (41.7) 54 (44.3) 
7 (3+4) 0 (0.0) 78 (5.7) 49 (5.3) 16 (2.5) 18 (4.0) 9 (3.0) 10 (5.3) 5 (4.1) 
7 (4+3) 0 (0.0) 30 (2.2) 14 (1.5) 12 (1.9) 6 (1.3) 4 (1.3) 1 (0.5) 3 (2.5) 
≥ 8 0 (0.0) 18 (1.3) 7 (0.8) 1 (0.2) 2 (0.4) 1 (0.3) 0 (0.0) 1 (0.8) 
NA 5 (0.3) 6 (0.4) 4 (0.4) 4 (0.6) 3 (0.7) 0 (0.0) 1 (0.5) 2 (1.6) 
Outcome, n (%)         
Progression 0 (0.0) 126 (9.2) 70 (7.6) 29 (4.5) 26 (5.8) 14 (4.7) 11 (5.9) 9 (7.4) 
No progression 1493 (100.0) 1244 (90.8) 852 (92.4) 615 (95.5) 421 (94.2) 284 (95.3) 176 (94.1) 113 (92.6) 
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Table 3: The change in the risk of delay of detection of higher grade disease for >1, >2, and >3 
years relative to an annual biopsy strategy. 
Policy Label Number of 
biopsies in 10 
years 
Increased risk of 
>12 months to 
detect grade 
progression* 
(%) 
Increased risk of 
>24 months to 
detect grade 
progression* 
(%) 
Increased risk of 
>36 months to 
detect grade 
progression* 
(%) 
A 9 1.5 1.2 0.5 
B 8 3.0 1.9 1.3 
C 7 3.4 2.7 1.4 
D 6 5.2 3.5 2.4 
E 5 7.1 6.6 5.6 
F 4 9.1 9.8 6.4 
G 3 17.0 11.6 9.6 
H 2 19.3 21.5 12.2 
I 1 21.3 25.3 17.8 
PRIAS 4 11.0 13.4 10.3 
UCSF1 7 4.9 6.1 2.9 
UCSF2 5 7.4 8.2 5.1 
*relative to annual biopsy strategy 
Note: annual biopsy strategy resulted in 13.5% risk of >12 months, 4.9% risk of >24 months, and 
1.8% risk of >36 months to detect grade progression. 
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Table 4: Results comparing hidden Markov model (HMM) parameter estimates from the Baum-
Welch algorithm to the true model parameter estimates from a known model. The 95% 
confidence interval is based on 1000 sets of simulated biopsy data with 1375 sequences per set. 
GS = Gleason score. 
Model Parameter True Value 
HMM 95% confidence 
interval estimate 
Proportion of patients with GS ≤ 6 at diagnosis 0.866 0.846 – 0.889 
Annual progression rate 0.040 0.033 – 0.039 
Sensitivity of biopsy to GS ≥ 7 prostate cancer 0.610 0.582 – 0.688 
Specificity of biopsy to GS ≥ 7 prostate cancer 0.986 0.980 – 0.988 
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Table 5: Bootstrapping results based on 30 different bootstrap samples of 1375 patients. GS = 
Gleason score. 
Model Parameter 95% confidence interval 
Proportion of patients with GS ≤ 6 at diagnosis 0.857 – 0.876 
Annual progression rate 0.032 – 0.040 
Sensitivity of biopsy to GS ≥ 7 prostate cancer 0.587 – 0.635 
Specificity of biopsy to GS ≥ 7 prostate cancer 0.980 – 0.988 
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